echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAHA: The association between high bililinemia and cardiovascular disease caused by the treatment of Azanave in people living with HIV.

    JAHA: The association between high bililinemia and cardiovascular disease caused by the treatment of Azanave in people living with HIV.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Serum bilium is negatively associated with cardiovascular risk.
    Azanave is an HIV protease inhibitor that competes against bilirin binding, a trait that provides an opportunity to assess whether selectively increasing bilirin has a heart-protective effect.
    A recent study published in JAHA, an authoritative journal in the field of cardiovascular disease, researchers sought to make it clear whether patients who received azanave had a lower risk of cardiovascular disease than those who received Trinave, an HIV protease inhibitor that does not increase serum bililubin.
    this is a retrospective queue study of 1,020 HIV patients.
    the study's main outcome occurred at the time of myocardial infarction or ischemic stroke.
    the average follow-up time was 6.6±3.4 years, of which 516 were treated with Azanave and 504 by Tyrinaway.
    total bililin levels (1.7 vs. 0.4 mg/dL;P<0.001) were significantly higher in Azanave therapists, and the average ischemia time was longer (10.2 vs. 9.4 years; P.lt;0.001).
    in Cox regression analysis, Azanave therapy (risk ratio is 0.38; 95% CI is 0.21-0.71; P is 0.00) 2) and serum bilirin (HR is 0.60; 95% CI is 0.41-0.89; P=0.011) are independently associated with a lower risk of ishemia events.
    it is worth noting that when Azanave and bilibin were included in the Cox regression model, the correlation between Azanave therapy and a lower risk of ischemia events was not significant (HR was 0.55; 95% CI was 0.24-1.29; P=0.169).
    risk of developing new cardiovascular disease was also significantly reduced in patients using Azanave (HR 0.53; 95% CI was 0.33-0.86; P=0.010), and the average time of death was longer (12.2 years vs. 10.8 years; P.lt;0.001).
    thus, the risk of cardiovascular disease in HIV patients treated with Azanave appears to be mediated by serum bilibin compared to patients treated with Trinave.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.